Skip to main content Skip to navigation
Purified Mouse Anti-BMPR-II
Product Details
Down Arrow Up Arrow

BD Transduction Laboratories™
Mouse (QC Testing), Human,Rat (Tested in Development)
Mouse IgG1
Mouse BMPR-II aa. 803-996
Western blot (Routinely Tested), Immunofluorescence (Not Recommended)
130 kDa
250 µg/ml
Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium azide.

Preparation And Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at -20°C.

Recommended Assay Procedures

Western blot: Please refer to

Product Notices

  1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
  2. Please refer to for technical protocols.
  3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
612292 Rev. 1
Antibody Details
Down Arrow Up Arrow

The transforming growth factor β (TGFβ)/activin/BMP family of growth factor plays a diverse and important role in growth, development, and differentiation. The receptors for this famiy of proteins are type I and II ser/thr kinase receptors. Bone morphogenetic protein receptors (BMPRs) include two type I receptors, BMPR-IA and BMPR-IB, and a type II receptor, BMPR-II. BMPR-II is a widely expressed receptor, with high mRNA expression during development in many tissues. BMPR-II transfected COS-1 cells show binding to BMP-7 (osteogenic protein-1) and BMP-4, and co-transfection with the type I receptor, ActR-I, leads to transcriptional activation in response to BMP-7. In addition, extracellular matrix proteins may regulate the expression of BMPR-II during angiogenesis, since fibrillar type I collagen induces BMPR-II expression in endothelial cells. In familial primary pulmonary hypertension, the BMPR-II gene is mutated in a manner that may disrupt ligand binding, kinase activity, and heteromeric dimer formation. Thus, BMPR-II may be an important mediator of BMP effects during growth and differentiation of endothelial cells.

612292 Rev. 1
Format Details
Down Arrow Up Arrow
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
612292 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (3)

  1. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet. 2000; 26(1):81-84. (Biology). View Reference
  2. Regazzoni C, Winterhalter KH, Rohrer L. Type I collagen induces expression of bone morphogenetic protein receptor type II. Biochem Biophys Res Commun. 2001; 283(2):316-322. (Biology). View Reference
  3. Rosenzweig BL, Imamura T, Okadome T, et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc Natl Acad Sci U S A. 1995; 92(17):7632-7636. (Biology). View Reference
612292 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.